Allogeneic stem cell transplantation improves survival in patients with AML characterized by a high allelic ratio of mutant FLT3-ITD

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F16%3A00089168" target="_blank" >RIV/00216224:14110/16:00089168 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.bbmt.2015.10.023" target="_blank" >http://dx.doi.org/10.1016/j.bbmt.2015.10.023</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.bbmt.2015.10.023" target="_blank" >10.1016/j.bbmt.2015.10.023</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Allogeneic stem cell transplantation improves survival in patients with AML characterized by a high allelic ratio of mutant FLT3-ITD

Popis výsledku v původním jazyce

Allogeneic transplantation (alloHCT) as post-remission therapy in patients with FLT3-ITD-positive intermediate-risk acute myeloid leukemia (AML) remains controversial. FLT3-ITD mutations are heterogeneous with respect to allelic ratio, location and length of the insertion, with a high mutant-to-wildtype ratio being consistently associated with inferior prognosis. We retrospectively analyzed the role of alloHCT in first remission in relationship to the allelic ratio and presence or absence of nucleophosmin 1 mutations (NPM1) in the SAL-AML2003 trial. FLT3-ITD mutations were detected in 209 patients and concomitant NPM1-mutations in 148 patients. Applying a pre-defined cutoff ratio of 0.8, AML was grouped into high- and low-ratio FLT3-ITD AML (HRFLT3-ITD and LRFLT3-ITD). Sixty-one patients (29%) were transplanted in first remission. Overall survival (OS) (HR 0.3, 95%CI 0.16 to 0.7, p=.004) and event-free survival (EFS) (HR 0.4, 95%CI 0.16 to 0.9, p=.

Název v anglickém jazyce

Allogeneic stem cell transplantation improves survival in patients with AML characterized by a high allelic ratio of mutant FLT3-ITD

Popis výsledku anglicky

Allogeneic transplantation (alloHCT) as post-remission therapy in patients with FLT3-ITD-positive intermediate-risk acute myeloid leukemia (AML) remains controversial. FLT3-ITD mutations are heterogeneous with respect to allelic ratio, location and length of the insertion, with a high mutant-to-wildtype ratio being consistently associated with inferior prognosis. We retrospectively analyzed the role of alloHCT in first remission in relationship to the allelic ratio and presence or absence of nucleophosmin 1 mutations (NPM1) in the SAL-AML2003 trial. FLT3-ITD mutations were detected in 209 patients and concomitant NPM1-mutations in 148 patients. Applying a pre-defined cutoff ratio of 0.8, AML was grouped into high- and low-ratio FLT3-ITD AML (HRFLT3-ITD and LRFLT3-ITD). Sixty-one patients (29%) were transplanted in first remission. Overall survival (OS) (HR 0.3, 95%CI 0.16 to 0.7, p=.004) and event-free survival (EFS) (HR 0.4, 95%CI 0.16 to 0.9, p=.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biology of Blood and Marrow Transplantation

ISSN

1083-8791

e-ISSN

—

Svazek periodika

22

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

462-469

Kód UT WoS článku

000370910200011

EID výsledku v databázi Scopus

—